July 6, 2021 -- Tetherex Pharmaceuticals has obtained an exclusive worldwide license for the development and commercialization of a novel single-cycle adenovirus vaccine platform from the Mayo Clinic. The platform will be used to target multiple infectious diseases beginning with a COVID-19 vaccine.
The single-cycle adenovirus platform was developed to enhance the expression of target antigens to amplify immune responses to infectious disease targets. Tetherex is investigating the technology in a phase I open-label study designed to assess the safety, reactogenicity, and immunogenicity of a single-cycle adenovirus vaccine candidate against COVID-19.
The trial is expected to enroll up to 80 healthy volunteers and includes both a single ascending dose group and multiple dose group via either intramuscular or intranasal administration.
Financial details regarding the license agreement were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
